High Lipoprotein(a) Heart Disease Study
Helping Daytona Beach patients explore new treatments for high lipoprotein(a) cardiovascular disease through safe, expertly managed clinical studies.
High Lipoprotein(a) Heart Disease Study
About This Study
We are conducting a research study to learn more about an investigational medication called Kylo-11 and how it may help people with heart or blood vessel disease who have high levels of lipoprotein(a), also known as Lp(a).
Lp(a) is a type of cholesterol that is not usually checked in routine blood tests but is known to increase the risk of heart attacks, strokes, and other cardiovascular problems. Currently, there are very limited treatment options specifically designed to lower Lp(a).
The goal of this study is to see if Kylo-11 can safely and effectively reduce Lp(a) levels and potentially improve heart health.
Study duration: The study is expected to last about 1 to 2 years for each participant, with the overall study continuing through 2028 as researchers collect results.
Why join? By joining this study, you may help researchers better understand how to treat a hidden risk factor for heart disease. You will also receive study-related care at no cost and contribute to advancements that could benefit many others in the future.
Study Eligibility
Who Can Participate?
Age
Age 18 to 80 years
Gender
All genders welcome
Condition
Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)
Location
Daytona Beach, FL
Enrolling Now
Apply for the Study
Fill out the form below to see if you qualify for our high lipoprotein(a) heart disease study in Daytona Beach. Participation is completely voluntary, and all study-related care will be provided at no cost to you.
Why Join?
- Access to new treatments before they are widely available
- No cost to participate — insurance is not required
- Compensation for your time and travel
- Personalized medical care from experienced physicians
Study Sponsor
Kylonova Biopharma
Long-acting siRNA therapies for cardiovascular risk
Kylonova Biopharma is developing Kylo-11, a long-acting small-interfering RNA (siRNA) therapy designed to lower lipoprotein(a) — a hard-to-treat cholesterol particle linked to heart disease, stroke, and blocked arteries.
Why Participate in a Clinical Trial?
Participating in a clinical trial at Arrow Clinical Trials in Daytona Beach is an opportunity to take charge of your health while helping advance medical science — all while under the care of experienced local physicians.
- Access to new treatments before they are widely available
- No cost to participate — insurance is not required
- Compensation for your time and travel
- Personalized medical care from experienced physicians
Daytona Cardiology Clinical Trials
Clinical Trial FAQs
What is lipoprotein(a), and why does it matter?
Lipoprotein(a), or Lp(a), is a type of cholesterol that can increase your risk of heart attack, stroke, and blocked arteries. Unlike other cholesterol types, it is largely determined by genetics and is harder to control with standard treatments.
What is Kylo-11?
Kylo-11 is an investigational medication (not yet approved by the FDA) designed to lower Lp(a) levels in the blood and potentially reduce cardiovascular risk.
Will I definitely receive the study medication?
Not necessarily. Participants are randomly assigned to receive either Kylo-11 or a placebo. This helps researchers fairly compare results.
Do I need to stop my current medications?
No. You will continue your regular medical care and medications unless the study doctor advises otherwise.
Is there any cost to participate?
No. Study-related care is provided at no cost, and some studies may offer compensation for time and travel.